As per the announcement made by a global healthcare company on 15 June, 2020, its sedative hypnotic drug formulation Propoven 2% (propofol 20 mg per mL) Emulsion 100mL, IV got emergency use authorization by FDA on 8 May, 2020 for COVID-19 patients.

The drug is now available for such patients. It will be dispersed via direct shipments with extra product-related materials, comprising of alert stickers on vial, wall charts, and; healthcare provider fact sheet, patient and caregiver fact sheet. 

A greater concentration presentation of propofol could be useful to providers in the management of COVID-19 patients who require mechanical ventilation, mentioned the senior vice president and regional medical director at the healthcare company. The significant information about the product’s differences from Diprivan 1% will be provided and other product materials will be made accessible to encourage the suitable use of this product in the US.

Any issues like medicine errors, adverse events and quality issues should be informed to FDA’s Medwatch and the company.